Skip to main content
Publications
Gilsenan A , Fortuny J , Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Harding A , Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu E, Plana E , Ruigomez A, Schink T, Ziemiecki R , Andrews EB. Cardiovascular safety of prucalopride in patients with chronic constipation: a multinational population-based cohort study . Drug Saf. 2019 Oct;42(10):1179-90. doi: 10.1007/s40264-019-00835-0
Gilsenan A , Fortuny J , Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Harding A , Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu I, Plana E , Ruigomez A, Schink T, Ziemiecki R , Andrews EB. Cardiovascular safety of prucalopride for chronic constipation: a multinational population-based cohort study . Presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):33. doi: 10.1002/pds.4864
Fortuny J , Gilsenan AW , Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E , Ruigomez A, Schink T, Ziemiecki R , Andrews EB. Cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort in a multinational study: study design and comparability of cohorts . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):627. doi: 10.1002/pds.4864
Cainzos-Achirica M, Ruigomez A, MacDonald T, Garcia-Rodriguez L, Fortuny J , Flynn RW, Plana E , Ziemiecki R , Andrews EB, Gilsenan A . Validation of major cardiovascular events in a multi-database post-authorization safety study of prucalopride . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):331. doi: 10.1002/pds.4864
Gilsenan A , Fortuny J , Plana E , Ruigomez A, Karlsson P, Flynn RWV, Cantero OF, Garcia-Rodriguez L, Linner L, Cainzos-Achirica M, Bartsch J , MacDonald T, Kieler H, Andrews EB. Non-interventional cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort initiating polyethylene glycol 3350 (PEG) . Poster presented at the 2018 Digestive Disease Week; June 3, 2018. Washington, DC.
McGrath LJ, Rulgomez A, Plana E , Fortuny J , Garcia-Rodriguez L, Rebordosa C , Varas-Lorenzo C, Ziemiecki R , Gilsenan AW , Andrews E. Characteristics of patients prescribed prucalopride versus an active comparator in England, Wales, and Northern Ireland . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):634.
Maurel J, Lopez-Pousa A, Calabuig S, Bague S, Del Muro XG, Sanjuan X, Rubio-Casadevall J, Cuatrecasas M, Martinez-Trufero J, Horndler C, Fra J, Valverde C, Redondo A, Poveda A, Sevilla I, Lainez N, Rubini M, Garcia-Albeniz X , Martin-Broto J, de Alava E. Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study . Clin Sarcoma Res. 2016 Jun 29;6:10. doi: 10.1186/s13569-016-0050-6
Rubio-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X , Calabuig S, Lopez-Pousa A, Del Muro JG, Fra J, Redondo A, Lainez N, Poveda A, Valverde C, De Juan A, Sevilla I, Casado A, Andres R, Cruz J, Martin-Broto J, Maurel J, Spanish Group for Research on Sarcoma. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS) . Ann Surg Oncol. 2015 Sep;22(9):2948-57. doi: 10.1245/s10434-014-4360-8
Masclee GMC, Valkoff VE, Straatman H, Herings R, Garbe E, Schink T, Kollhorst B, Arfe A, Lucchi S, Villa M, Castellsague J, Perez-Gutthann S , Varas-Lorenzo C, Schade R, Schuemie M, Vergouwe Y, Steyerberg E, Sturkenboom M, Romio S. Individualized NSAID prescribing based on gastrointestinal and cardiovascular risks: a decision model in the SOS project . Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA. [abstract] Pharmacoepidemiol Drug Saf. 2015 Sep; 24(S1):36-7. doi: 10.1002/pds.3838
Long MD, Hutfless S, Kappelman MD, Khalili H, Kaplan GG, Bernstein CN, Colombel JF, Gower-Rousseau C, Herrinton L, Velayos F, Loftus EVJr, Ananthakrishnan AN, Nguyen GC, Sonnenberg A, Chan A, Sandler RS, Atreja A, Shah SA, Rothman KJ , Leleiko NS, Bright R, Boffetta P, Myers KD, Sands BE. Challenges in designing a national surveillance program for inflammatory bowel disease in the United States . Inflamm Bowel Dis. 2014 Feb;20(2):398-415. doi: 10.1097/01.MIB.0000435441.30107.8b
Pisa F, Castellsague J, Drigo D, Riera-Guardia N , Giangreco M, Rosolen V, Clagnan E, Zanier L, Perez-Gutthann S , Barbone F. Accuracy of International Classification of Diseases, 9th Revision, Clinical Modification codes for upper gastrointestinal complications varied by position and age: a validation study in a cohort of nonsteroidal anti-inflammatory drugs users in Friuli Venezia Giulia, Italy . Pharmacoepidemiol Drug Saf. 2013 Aug 20;22(11):1195-204.
Castellsague J, Pisa F, Rosolen V, Drigo D, Riera Guardia N , Giangreco M, Clagnan E, Tosolini F, Zanier L, Barbone F, Perez-Gutthann S . Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy . Pharmacoepidemiol Drug Saf. 2013 Apr 22;22(4):365-75.
Castellsague J, Pisa F, Rosolen V, Riera-Guardia N , Giangreco M, Clagnan E, Tosolini F, Zanier L, Barbone F, Perez-Gutthann S . Use of nimesulide, other nsaids and the risk of upper gastrointestinal complications in Friuli Venezia Giulia, Italy. Analysis of cases with codes with high positive predictive value . Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2011. Chicago, IL. [abstract] Pharmacoepidemiol Drug Saf. 2011 Aug; 20(S1):S178.
Pisa F, Drigo D, Riera-Guardia N , Castellsague J, Rosolen V, Clagnan E, Tosolini F, Zanier L, Perez-Gutthann S , Barbone F. Validation of primary and secondary ICD-9-cm codes for upper gastrointestinal complications in Friuli Venezia Giulia, Italy . Poster presented at the 27th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 1, 2011. [abstract] Pharmacoepidemiol Drug Saf. 20(Suppl. 1):S172.
Arana A , Allen S, Burkowitz J, Fantoni V, Ghatnekar O, Rico MT, Vanhaverbeke N, Wentworth CE, Brosa M, Arellano FM. Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation . Drug Saf. 2010 Jun;33(6):489-501.
Hoyo C, Schildkraut JM, Murphy SK, Chow WH, Vaughan TL, Risch H, Marks JR, Jirtle RL, Calingaert B , Mayne S, Fraumeni, Jr. J, Gammon MD. IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas . Int J Cancer. 2009 Dec 1;125(11):2673-8.
Huerta C, Montoro MA, Sanchez B, Rivero E , Lievano F, Garcia-Rodriguez LA. Incidence and risk factors for intestinal ischemia . Poster presented at the 22nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2006. Lisbon, Portugal. [abstract] Pharmacoepidemiol Drug Saf. 2006 Aug; 15(Suppl 1):S268.
Sakamoto C, Sugano K, Ota S, Sakaki N, Takahashi S, Yoshida Y, Tsukui T, Osawa H, Sakurai Y, Yoshino J, Mizokami Y, Mine T, Arakawa T, Kuwayama H, Saigenji K, Yakabi K, Chiba T, Shimosegawa T, Sheehan JE, Perez-Gutthann S , Yamaguchi T, Kaufman DW, Sato T, Kubota K, Terano A. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan . Eur J Clin Pharmacol. 2006;62(9):765-72.